Healthcare Services

Global Immunogenomics Market Anticipated To Grow To $12.72 Billion By 2030 At 15.8% CAGR

May 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Forecasted Market Size Of The Immunogenomics Market Compare Between 2026 And 2030?

The immunogenomics market has experienced substantial expansion in its size over recent years. Projections indicate it will expand from $6.09 billion in 2025 to reach $7.07 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.1%. This historical growth can be attributed to several factors, including progress in genomic sequencing technologies, an expanding comprehension of genetic variations linked to immunity, the broadening scope of research in oncology and infectious diseases, increased financial support for research, and the accessibility of high-throughput genomic instruments.

The immunogenomics market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $12.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. Factors driving this growth during the forecast period include a surging demand for precision medicine solutions, the escalating development of personalized vaccines and immunotherapies, the widening scope of translational immunogenomics research, increasing integration of multi-omics data, and the heightened uptake of cloud-based genomic analytics. Key trends anticipated within this period involve the expanding adoption of next-generation sequencing for immune profiling, the increasing utilization of bioinformatics tools for analyzing immune data, a deepening focus on personalized immunotherapies, the enlargement of genomic databases for immune research, and the advanced integration of AI into immunogenomic studies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28247&type=smp

Which Major Factors Are Contributing To The Development Of The Immunogenomics Market?

The expanding occurrence of infectious diseases is projected to fuel the advancement of the immunogenomics market moving ahead. These diseases are ailments resulting from detrimental microorganisms like bacteria, viruses, fungi, or parasites, which can be transmitted between individuals through direct or indirect contact. The growth in infectious disease prevalence stems from heightened global travel, enabling swift dissemination of pathogens across national boundaries. Immunogenomics improves the handling of infectious diseases by allowing for accurate examination of a host’s immune reactions and genetic predispositions. This field lessens experimental treatment approaches by pinpointing immune factors specific to each patient, thereby advancing diagnostics, vaccine creation, and tailored therapeutic plans. For example, in February 2024, data from the UK Health Security Agency, a government body based in the UK, indicated that tuberculosis (a communicable bacterial infection mainly impacting the lungs) instances in England climbed to 4,850 in 2023, marking a 10.7% rise from 4,380 cases recorded in 2022. Consequently, the expanding incidence of infectious diseases is fostering the expansion of the immunogenomics market.

How Are Different Segment Groups Identified Within The Immunogenomics Market?

The immunogenomics market covered in this report is segmented –

1) By Product Type: Instruments, Consumables, Software, Services

2) By Technology: Next-Generation Sequencing, Microarray, Polymerase Chain Reaction, Other Technologies

3) By Application: Oncology, Infectious Diseases, Autoimmune Disorders, Transplantation, Other Applications

4) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Instruments: Sequencers, Microarray scanners, Flow cytometers

2) By Consumables: Reagents, Kits, Assay panels

3) By Software: Data analysis software, Bioinformatics tools, Visualization platforms

4) By Services: Sequencing services, Genomic profiling, Bioinformatics support

Which Trends Are Supporting The Evolution Of The Immunogenomics Market?

Major companies active within the immunogenomics sector are prioritizing the creation of sophisticated solutions, notably a vaccine target prediction system. This system facilitates automated, comprehensive vaccine design and refines vaccine constructs through the assurance of ideal antigen sequences. Operating as a computational framework, it leverages bioinformatics algorithms alongside genomic and immunomic datasets to pinpoint potential antigen molecules originating from pathogens or cancer cells. Furthermore, it assesses their structural attributes to rank and select the most effective vaccine candidates capable of eliciting robust protective immune responses. For illustration, in September 2024, Denmark-based biotechnology firm Evaxion Biotech A/S, specializing in AI-driven immunotherapy and vaccine development, introduced its clinically validated AI-Immunology platform, an enhanced EDEN artificial intelligence prediction model. This model incorporates a novel toxin antigen predictor, boosting the precision and dependability of identifying bacterial toxin antigens for the development of future bacterial vaccines. Additionally, the platform is capable of simulating the immune system to generate tailored and advanced immunotherapies, having demonstrated significant correlations between its AI-powered predictions and actual clinical results.

Who Are The Major Companies Operating In The Immunogenomics Market?

Major companies operating in the immunogenomics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Illumina Inc., BGI Group, GenScript Biotech Corporation, CareDx Inc., Oxford Nanopore Technologies plc, Genewiz LLC, Adaptive Biotechnologies Corporation, GenomOncology LLC, Personalis Inc., Variantyx Inc., CD Genomics Inc., Sengenics Corporation, GeneCentric Therapeutics Inc., Immunogenomics Inc., ImmuQuad Biotechnologies Inc., Neomics Pharmaceuticals LLC, Yemaachi Biotech Ltd., BioAnalytica Biotechnology Systems Inc.

Access The Complete Immunogenomics Market Report:

https://www.thebusinessresearchcompany.com/report/immunogenomics-global-market-report

Which Region Accounts For The Highest Share Of The Immunogenomics Market?

North America was the largest region in the immunogenomics market in 2025. The regions covered in the immunogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Immunogenomics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=28247&type=smp

Browse Through More Reports Similar to the Global Immunogenomics Market 2026, By The Business Research Company

Immunoassay Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Automated Immunoassay Analyzers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/automated-immunoassay-analyzers-global-market-report

Immunomodulator Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunomodulator-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795